|
1
|
Garcia JA and Rini BI: Recent progress in
the management of advanced renal cell carcinoma. CA Cancer J Clin.
57:112–125. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili
R, Bjarnason GA, et al: Overall survival and updated results for
sunitinib compared with interferon alfa in patients with metastatic
renal cell carcinoma. J Clin Oncol. 27:3584–3590. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Naito S, Yamamoto N, Takayama T, Muramoto
M, Shinohara N, Nishiyama K, Takahashi A, Maruyama R, Saika T,
Hoshi S, et al: Prognosis of Japanese metastatic renal cell
carcinoma patients in the cytokine era: A cooperative group report
of 1463 patients. Eur Urol. 57:317–326. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Escudier B, Eisen T, Stadler WM, Szczylik
C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA,
et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N
Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
General rule for clinical and pathological
studies on renal cell carcinoma, the 4th edition, . The Japanese
Urological Association, The Japanese Society of Pathology, Japan
Radiological Society. 2011.
|
|
7
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
National Cancer Institute, . Cancer
Therapy Evaluation Program. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40July
5–2019
|
|
9
|
Eichelberg C, Heuer R, Chun FK, Hinrichs
K, Zacharias M, Huland H and Heinzer H: Sequential use of the
tyrosine kinase inhibitors sorafenib and sunitinib in metastatic
renal cell carcinoma: A retrospective outcome analysis. Eur Urol.
54:1373–1378. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dudek AZ, Zolnierek J, Dham A, Lindgren BR
and Szczylik C: Sequential therapy with sorafenib and sunitinib in
renal cell carcinoma. Cancer. 115:61–67. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sablin MP, Negrier S, Ravaud A, Oudard S,
Balleyguier C, Gautier J, Celier C, Medioni J and Escudier B:
Sequential sorafenib and sunitinib for renal cell carcinoma. J
Urol. 182:29–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miyake H, Kusuda Y, Harada K, Sakai I and
Fujisawa M: Third-line sunitinib following sequential use of
cytokine therapy and sorafenib in Japanese patients with metastatic
renal cell carcinoma. Int J Clin Oncol. 18:81–86. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mizukami Y, Kohgo Y and Chung DC: Hypoxia
inducible factor-1 independent pathways in tumor angiogenesis. Clin
Cancer Res. 13:5670–5674. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Motzer RJ, Bacik J, Murphy BA, Russo P and
Mazumdar M: Interferon-alfa as a comparative treatment for clinical
trials of new therapies against advanced renal cell carcinoma. J
Clin Oncol. 20:289–296. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fujita T, Iwamura M, Ishii D, Tabata K,
Matsumoto K, Yoshida K and Baba S: C-reactive protein as a
prognostic marker for advanced renal cell carcinoma treated with
sunitinib. Int J Urol. 19:908–913. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gore ME, Szczylik C, Porta C, Bracarda S,
Bjamason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D,
et al: Safety and efficacy of sunitinib for metastatic renal-cell
carcinoma: An expanded-access trial. Lancet Oncol. 10:757–763.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kawashima A, Tsujimura A, Takayama H, Arai
Y, Nin M, Tanigawa G, Yasunaga Y, Mukai M, Uemura M, Nakai Y, et
al: Importance of continuing therapy and maintaining one-month
relative dose intensity in sunitinib therapy for metastatic renal
cell carcinoma. Med Oncol. 29:3298–3305. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Porta C, Procopio G, Cartenì G, Sabbatini
R, Bearz A, Chiappino I, Ruggeri EM, Re GL, Ricotta R, Zustovich F,
et al: Sequential use of sorafenib and sunitinib in advanced
renal-cell carcinoma (RCC): An Italian multicentre retrospective
analysis of 189 patient cases. BJU Int. 108:E250–E257. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stenner F, Chastonay R, Liewen H, Haile
SR, Cathomas R, Rothermundt C, Siciliano RD, Stoll S, Knuth A,
Buchler T, et al: A pooled analysis of sequential therapies with
sorafenib and sunitinib in metastatic renal cell carcinoma.
Oncology. 82:333–340. 2012. View Article : Google Scholar : PubMed/NCBI
|
